argenx SE

NasdaqGS:ARGX Stock Report

Market Cap: US$35.2b

argenx Past Earnings Performance

Past criteria checks 3/6

argenx has been growing earnings at an average annual rate of 34.8%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 55.3% per year. argenx's return on equity is 19.4%, and it has net margins of 40.3%.

Key information

34.84%

Earnings growth rate

36.91%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate55.34%
Return on equity19.35%
Net Margin40.26%
Next Earnings Update31 Jul 2025

Recent past performance updates

Recent updates

Argenx's CIDP Challenge: A Safety Signal Points To Operational Refinement, Not Ruin

Jun 30

Argenx: The Magic May Be Already Priced In

Mar 24

argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent

Feb 27

argenx: Lofty Valuation Diminishes Appeal Amid Autoimmune Expansion (Rating Downgrade)

Jan 23

Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat

Oct 31

argenx: Myositis Data Could Add Billions In Value

Sep 25

Argenx: Strong Setup For Outperformance In 2025

Jun 28

argenx: Innovation Over Losses In Autoimmune Arena

May 07

argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion

Feb 01

Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod

Sep 21

Argenx's neuromuscular disorder drug Vyvgart wins approval in EU

Aug 11

Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M

Jul 28

argenx: A Very Good Start For Vyvgart

May 25

argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain

May 18

argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers

Mar 07

argenx: Vyvgart's Approval A Key Step For Continued Value Creation

Dec 22

argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers

Nov 30

argenx: R&D Day Goes Unnoticed

Aug 23

argenx: Next Phase Of Growth With Efgartigimod And ARGX-117

Jun 30

Revenue & Expenses Breakdown

How argenx makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:ARGX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 252,6431,0641,0960
31 Dec 242,2488331,0550
30 Sep 241,909-409780
30 Jun 241,660-2048920
31 Mar 241,451-3287990
31 Dec 231,269-2957120
30 Sep 231,029-2346380
30 Jun 23835-3975550
31 Mar 23639-5115200
31 Dec 22441-7104720
30 Sep 22286-9094340
30 Jun 22146-9074070
31 Mar 22381-5953520
31 Dec 21528-4083080
30 Sep 21510-3732700
30 Jun 21526-3192330
31 Mar 21206-5732040
31 Dec 2062-6081720
30 Sep 2075-5351440
30 Jun 2070-3591100
31 Mar 2073-275860
31 Dec 1993-181720
30 Sep 1972-109560
30 Jun 1968-104490
31 Mar 1970-47370
31 Dec 1833-76310
30 Sep 1841-56270
30 Jun 1844-47220
31 Mar 1850-46180
31 Dec 1749-34150
30 Sep 1742-30110
30 Jun 1739-25100
31 Mar 1723-29100
31 Dec 1618-2270
30 Sep 1617-2070
30 Jun 1614-1760
31 Mar 1612-1760
31 Dec 1511-1750
30 Sep 1510-1650
30 Jun 159-1450
31 Mar 157-1240
31 Dec 147-1240
30 Sep 146-1040

Quality Earnings: ARGX has high quality earnings.

Growing Profit Margin: ARGX became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ARGX has become profitable over the past 5 years, growing earnings by 34.8% per year.

Accelerating Growth: ARGX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ARGX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (21.7%).

Return on Equity

High ROE: ARGX's Return on Equity (19.4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/23 21:29
End of Day Share Price 2025/07/23 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

argenx SE is covered by 50 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Charles PitmanBarclays
Richard ParkesBNP Paribas Exane